Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04779866
Other study ID # NCT09384
Secondary ID 3R01AT009384-04S
Status Completed
Phase N/A
First received
Last updated
Start date March 30, 2021
Est. completion date June 1, 2023

Study information

Verified date July 2023
Source Baylor University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The long-range goal is to identify an efficacious and practical intervention to improve sleep quality and duration for family caregivers of individuals with Alzheimer's disease and related dementias (ADRD). The main goal of this study is to determine feasibility of a self-administered hypnosis intervention with caregivers of individuals with ADRD by randomizing eligible participants into one of two study arms, self-administered hypnosis (treatment group) or sham white noise hypnosis (control group). The investigators are also examining the feasibility of accrual, outcome measures (diaries, actigraphy) and study design.


Description:

Study Objectives Aim 1: Determine the accrual, retention, adherence and feasibility, and randomization to the self-administered hypnosis program among caregivers of individuals with ADRD. Feasibility will be determined by (1) drop-out rate, (2) participants' rating of the program, and (3) participants' rating of treatment satisfaction. Adherence will be determined through at-home practice logs. Essential experience on accrual and retention data as well. Aim 2: Determine feasibility of measures: PSQI, actigraphy recordings, and sleep diaries to assess sleep quality and duration, as well as feasibility of secondary self-report outcome measures of insomnia severity, stress, cognition, and pain among caregivers. Aim 3: Determine perceptions of hypnosis and potential barriers for the caregiver population and feedback. Participant Selection and Recruitment Plan A sample of 20 caregivers, both male and female, of individuals with ADRD, who suffer from poor sleep will be enrolled in the study. A screening checklist will be used for screening participants who are interested. Potential participants will be identified (1) via advertisements and press releases, (2) via physician referral, and (3) targeted mailings. Participants eligibility will be determined by criteria listed on a screening checklist. The investigators have used these strategies in prior studies and have demonstrated ability to accrue the required number of participants.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 1, 2023
Est. primary completion date June 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Active caregiver to an individual with Alzheimer's disease or its related dementias 2. Self-reported sleep duration of 6 or less hours per day/night as indicated on the PSQI 3. Signed informed consent 4. Access to a computer or mobile device with reliable Internet connection that will allow for the completion of study visits and study materials online Exclusion Criteria: 1. Use of any prescription or over-the-counter therapy for sleep 2. Severe or unstable medical or psychiatric illness 3. Current use of hypnosis for any condition 4. Inability to speak or understand English

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Self-Administered Hypnosis
Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
Self-Administered White Noise Hypnosis
Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.

Locations

Country Name City State
United States Baylor University Waco Texas

Sponsors (2)

Lead Sponsor Collaborator
Baylor University National Center for Complementary and Integrative Health (NCCIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Post-Participation Interview In order to gather qualitative data to improve future studies, participants will be asked to participate in a post-participation interview. An experienced and trained doctoral student will conduct interviews and create summary statements regarding topics including ease of use of the intervention, barriers of using the audio recordings, finding the time to practice, and improvement of the intervention. Interviews will be recorded and transcripts will be typed out. 1 week
Primary Self-Hypnosis Practice Log Participants will be instructed in daily practice of hypnosis and asked to keep a daily self-hypnosis practice form during the intervention period. Through study completion, an average of 7 weeks
Primary Program Rating Scale In order to assess participants' perceptions of the value of the hypnosis program they receive, they will be asked "How do participants rate this hypnosis program overall in regard to ease of use?" and "How do participants rate this hypnosis program overall in regard to improving sleep?" Responses will be given on a 10-point scale ranging from 1 (Poor) to 10 (Excellent) at follow-up. One week
Primary Treatment Satisfaction Scale Participants will be asked to rate their overall level of satisfaction with the intervention. A 10-point VAS scale anchored with 0 "Completely Dissatisfied" to 10 "Completely Satisfied" will be given at follow-up. One week
Primary Wrist Actigraphy Wrist actigraphy is a widely used and well-validated measure of sleep duration. Participants will be asked to wear an actigraph (Actiwatch Spectrum Pro), resembling a wrist watch, on their non-dominant wrist. A motion detection device located within the actigraph records movement. After data is collected and stored within the actigraph it can be analyzed with the Actiware software program. This program uses a series of logarithms to measure various factors associated with sleep quality, such as total sleep duration, sleep efficiency, sleep onset latency, and the number of times participants woke during the night. For the present study, participants will be asked to wear the actigraph for one week at baseline and for one week at follow-up. up to 2 weeks
Primary Pittsburgh Sleep Quality Index Participants will be asked to complete the Pittsburgh Sleep Quality Index (PSQI) during screening and at follow-up to measure sleep quality. The PSQI is a 19-item self-report inventory designed to measure sleep quality. The 19 items are grouped into 7 subscales: 1) sleep quality, 2) sleep efficiency, 3) daytime dysfunction, 4) sleep latency, 5) sleep disturbances, 6) sleep duration, and 7) use of sleep medication. These seven subscales are scored on a scale of 0-3 with higher scores indicating greater sleep pathology. Cronbach's alphas for the PSQI range from .70 to .8024. up to 2 weeks
Primary Daily Sleep Diaries A daily sleep diary where participants record time awake and time to bed will be used. Participants will be asked to complete a daily sleep diary upon awakening each morning for a week at baseline, daily during the intervention weeks, and a week at follow-up. Through study completion, an average of 7 weeks
Primary Epworth Sleepiness Scale Participants will be asked to complete the Epworth Sleepiness Scale (ESS) to assess daytime sleepiness. The ESS is an 8-item self-report measure that asks participants to indicate how likely they are to fall asleep while engaging in eight different everyday activities (e.g., watching television, sitting in traffic). Items are scored on a scale from 0-3 with higher scores indicating a greater probability of falling asleep. Previous research indicates that the ESS has a Cronbach's alpha of .8827. Through study completion, an average of 7 weeks
Primary Sleep Environment Questionnaire Participants will be asked to complete the Sleep Environment Questionnaire during baseline and at follow-up. The Sleep Environment Questionnaire is an 11-item self-report measure that asks about the environment in which a person sleeps. Response options include "True," "False," or "Not Applicable." Through study completion, an average of 7 weeks
Primary Attitudes Toward Hypnosis Scale The 14-item Attitudes Toward Hypnosis Scale will be used to assess attitudes toward hypnosis at baseline and at follow-up. This scale has shown internal consistency in previous studies, Cronbach's alpha = .8128. A total attitude toward hypnosis score will be calculated for each participant by summing scores across the 14 items with higher scores indicating more positive attitudes toward hypnosis. Through study completion, an average of 7 weeks
Secondary Insomnia Severity Index Participants will be asked to complete the Insomnia Severity Index (ISS) to measure insomnia symptom severity. The ISS consists of seven items that measure the severity of sleep onset, sleep maintenance, and early morning awakening problems, as well as the participant's satisfaction with her current sleep pattern, the extent to which lack of sleep interferes with daily functioning, how noticeable this impairment is to other people, and the extent to which the participant is worried or distressed about their lack of sleep. Items are scored on a scale from 0-4 with total score of 15 or higher indicating the presence of clinical insomnia25. Past research indicates that internal reliability estimates for the ISI range from .74 to .7825. Through study completion, an average of 7 weeks
Secondary Perceived Stress Scale The Perceived Stress Scale (PSS) will be used to measure stress at baseline and follow-up. The PSS includes 14 items that assess levels of perceived stress and to what degree individuals perceive events in their life as stressful during the previous month. Higher scores indicate greater stress. Past research indicates that Cronbach's alpha for the PSS is .8526. Through study completion, an average of 7 weeks
Secondary PROMIS Cognitive Function - Short Form Cognition will be assessed using the PROMIS Cognitive Function - Short Form Scale. This scale includes 8 items and measures self-reported cognitive functioning during the past 7 days. Items are scored from a scale of 1 (Very Often) to 5 (Never). Items are summed to create a total score and higher scores indicate better cognitive functioning. Through study completion, an average of 7 weeks
Secondary Pain Visual Analog Scale Participants will be asked to rate their pain on a 100-mm visual analog scale (VAS) during baseline and follow-up. Participants will be asked to place an "x" along the 100-mm line to indicate the severity of their pain over the past week, with the lower end of the scale being anchored by the phrase "no pain" and the upper end of the scale being anchored by the phrase "the most intense pain possible." Through study completion, an average of 7 weeks
Secondary Motivation Scale Motivation to use hypnosis is an important factor to be assessed. Motivation to use hypnosis to improve sleep quality will be assessed at baseline using a numerical rating scale that states, "How motivated are participants to use hypnosis to improve sleep?" This item will be rated on a scale of 1 (Not Motivated at All) to 10 (Very Motivated). One week during baseline week
See also
  Status Clinical Trial Phase
Completed NCT04583033 - Sleep Well for Healthy Brain N/A
Completed NCT06154629 - Effect of a Botanical Ingredient in Healthy Subjects With Anxiety and Poor Sleep Quality N/A
Completed NCT06154616 - Efficacy of Different Types of Milk in Improving Sleep Quality in Subjects With Sleep Problems (Milca) N/A
Completed NCT05838339 - Are You Daydreaming? N/A
Terminated NCT01966315 - The Comparison of Dexmedetomidine and Midazolam for the Sleep in Intensive Care Unit
Completed NCT00253890 - Insomnia and Drug Relapse Risk Phase 3
Completed NCT05478980 - The Effects of a Multi-ingredient Night-time Tea on Sleep Quality, Wellbeing and Markers of Immune Function N/A
Withdrawn NCT01978340 - Eval EarlySense Bet Lowenstein Sleeplab N/A
Completed NCT06107049 - the Effect of Probiotic on Sleep Quality Management N/A
Not yet recruiting NCT03724474 - SMART Technology to Promote Heart Health in Midlife Adults N/A
Not yet recruiting NCT04311372 - Sleep Wellness Program - University REST N/A
Enrolling by invitation NCT05155787 - Neurofeedback Training (NFT) on Sleep Quality and Cognitive Function Performance Among HIV-infected Persons N/A
Completed NCT02783027 - The SleepTrackTXT2 Randomized Trial With Air-medical Personnel N/A
Completed NCT00460993 - Efficacy & Safety of Eszopiclone (Lunesta) in Nursing Home Patients Phase 4
Completed NCT02825589 - BIA-Guided Dry Weight Assessment on Sleep Quality in Chronic Hemodialysis Patients N/A
Completed NCT04033601 - A Novel Strategy to Develop a Rapid Screen, Simple Subgrouping and Precise Intervention Model for Older Adults With Poor Sleep Quality N/A
Completed NCT02042001 - Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects Phase 4
Completed NCT01832155 - Yoga for Managing Knee Osteoarthritis in Older Women: a Feasibility Study N/A
Completed NCT05609890 - Novel Formulation for Sleep Among People With Poor Sleep Quality N/A
Completed NCT05215717 - Hypnosis for Sleep Quality for Individuals With Mild Cognitive Impairment N/A